



At-the-Market (ATM) agreement with Acuity Capital

Highlights

- **At-the-Market Subscription Agreement signed**
- **Up to \$5 million of standby equity capital**
- **Utilisation at Noxopharm's discretion**

Sydney, 27 February 2026: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the signing of an At-the-Market Subscription Agreement (ATM) agreement with Acuity Capital.

The ATM provides Noxopharm with up to \$5 million of standby equity capital over the next five years to 31 July 2031.

Under the terms of the agreement Noxopharm has full discretion as to whether or not to utilise the ATM, the maximum number of shares to be issued, the minimum issue price of shares, and the timing of each subscription (if any).

There are no requirements on Noxopharm to utilise the ATM, and Noxopharm may terminate the ATM at any time without cost or penalty. Additionally, Acuity Capital and the ATM do not place any restrictions at any time on Noxopharm raising capital through other methods.

If Noxopharm decides to utilise the ATM, it can set an issue price floor at its sole discretion, with the final issue price being calculated as the greater of the nominated floor price and up to a 10% discount to a Volume Weighted Average Price (VWAP) over a period of Noxopharm's choosing, again at its sole discretion.

As security for the ATM, Noxopharm has agreed to place 15,000,000 fully paid ordinary NOX ASX shares from its LR7.1 capacity at nil cash consideration to Acuity Capital. Upon early termination or maturity of the ATM, Noxopharm may buy back and cancel the shares placed as security for no cash consideration, subject to shareholder approval.

An Appendix 2A will be released in conjunction with this announcement.

-ENDS-

About the Sofra technology platform

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.



[Sofra technology](#) has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.